免疫检查点抑制剂单药或联合化疗治疗早期非小细胞肺癌的系统综述与Meta分析:临床病理因素的影响及治疗策略间的间接比较
该系统综述与Meta分析纳入8项随机对照试验共4661例早期非小细胞肺癌患者,评估免疫检查点抑制剂单药或联合铂类化疗的疗效。新辅助/围手术期免疫检查点抑制剂联合铂类化疗较铂类化疗显著改善病理完全缓解、无事件生存、总生存、主要病理缓解和R0切除;辅助免疫检查点抑制剂较安慰剂显著改善无病生存。PD-L1状态、病理完全缓解和分期与无事件生存存在显著亚组交互作用,间接比较显示新辅助与围手术期策略的无事件生存和总生存无差异。
要点
- 新辅助/围手术期免疫检查点抑制剂联合铂类化疗较铂类化疗显著改善病理完全缓解、无事件生存、总生存、主要病理缓解和R0切除。
- 辅助免疫检查点抑制剂较安慰剂显著改善无病生存。
- PD-L1状态、病理完全缓解和分期与无事件生存存在显著亚组交互作用;PD-L1阴性患者中仍有14%获得病理完全缓解。
核心结论
- PD-L1状态、病理完全缓解和分期影响新辅助/围手术期免疫检查点抑制剂的生存获益。
- 将新辅助/围手术期免疫检查点抑制剂限制于PD-L1阳性患者可能使PD-L1阴性亚组无法获得病理完全缓解和长期获益。
- 新辅助与围手术期策略可能等效。
研究设计与样本
- 系统综述与Meta分析,纳入8项随机对照试验(2项新辅助、4项围手术期、2项辅助),共4661例早期非小细胞肺癌患者。
- 主要结局为新辅助/围手术期的病理完全缓解和无事件生存,以及辅助治疗的无病生存。
主要发现
- 新辅助/围手术期免疫检查点抑制剂联合铂类化疗较铂类化疗显著改善病理完全缓解、无事件生存、总生存、主要病理缓解和R0切除。
- 辅助免疫检查点抑制剂较安慰剂显著改善无病生存。
- 无事件生存的亚组交互作用:PD-L1状态(χ2=10.72,P=0.005)、病理完全缓解(χ2=17.80,P<0.0001)、分期(χ2=4.46,P=0.003)。
- 病理完全缓解方面未发现PD-L1状态的差异,PD-L1阴性肿瘤患者中14%仍获得病理完全缓解。
- 辅助免疫检查点抑制剂的无病生存未发现PD-L1状态交互作用。
关键数值与推荐
- 新辅助/围手术期免疫检查点抑制剂联合铂类化疗较铂类化疗显著改善病理完全缓解、无事件生存、总生存、主要病理缓解和R0切除。
- 辅助免疫检查点抑制剂较安慰剂显著改善无病生存。
- 无事件生存的亚组交互作用:PD-L1状态(χ2=10.72,P=0.005)、病理完全缓解(χ2=17.80,P<0.0001)、分期(χ2=4.46,P=0.003)。
- PD-L1阴性肿瘤患者中14%仍获得病理完全缓解。
- 间接比较显示新辅助与围手术期免疫检查点抑制剂联合铂类化疗的无事件生存和总生存无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In non-small cell lung cancer (NSCLC), the immune checkpoint inhibitors (ICI) revolution is rapidly moving from metastatic to early-stage, however, the impact of clinicopathological variables and optimal treatment sequencing remain unclear. METHODS: Randomized controlled trials (RCTs) in patients with early-stage NSCLC treated with ICI as single agent or in combination with platinum-based chemotherapy (PCT) were included. Primary outcomes were pathological complete response (pCR), event free survival (EFS) (neoadjuvant/perioperative), and disease-free survival (DFS) (adjuvant). Secondary outcomes were major pathological response (MPR), overall survival (OS), toxicity, surgical outcomes (neoadjuvant/perioperative); OS and toxicity (adjuvant). An additional secondary endpoint was to compare EFS and OS between neoadjuvant and perioperative strategies. RESULTS: 8 RCTs (2 neoadjuvant, 4 perioperative, 2 adjuvant) (4661 participants) were included. Neoadjuvant/perioperative ICI+PCT significantly improved pCR, EFS, OS, MPR and R0 resection compared to PCT. Adjuvant ICI significantly improved DFS compared to placebo. There was a significant subgroup interaction by PD-L1 status (χ2 = 10.72, P = 0.005), pCR (χ2 = 17.80, P < 0.0001), and stage (χ2 = 4.46, P = 0.003) for EFS. No difference according to PD-L1 status was found for pCR, with 14% of patients having PD-L1 negative tumors still experiencing a pCR. No interaction by PD-L1 status was found for DFS upon adjuvant ICI. Indirect comparison showed no difference in EFS and OS between neoadjuvant and perioperative ICI+PCT. CONCLUSIONS: PD-L1 status, pCR and stage impact on survival upon neoadjuvant/perioperative ICI. The restriction of neoadjuvant/perioperative ICI to PD-L1 + patients could preclude pCR and long-term benefit in the PD-L1- subgroup. Neoadjuvant and perioperative could be equivalent strategies.
引用
- Nuccio A, Viscardi G, Salomone F, et al. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023. PMID: 37948842. doi:10.1016/j.ejca.2023.113404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。